Cone Health Women's Hospital

New Study Shows High Patient Satisfaction and Outcomes After Outpatient Joint Arthroplasty at Academic Medical Centers

Retrieved on: 
Mardi, mars 7, 2023
TKA, MD, Cone Health Women's Hospital, American Academy, Hip, Approximation error, AMC, Patient, KOOS, AAOS, THA, Abdominal ultrasonography, Academic medical centre, Literature, UKA, Risk, Faculty, Patient satisfaction, TJA, Pros, Pain, Harvard Medical School, William H. Harris (orthopaedic surgeon), Length of stay, Hospital, Observation, United, Academic Medical Center (Amsterdam), Brigham

LAS VEGAS, March 7, 2023 /PRNewswire/ -- In the first study to establish patient satisfaction after outpatient total joint arthroplasty (TJA) in an academic medical center (AMC) setting, patients indicated they were very likely to undergo the outpatient procedure again and had high patient reported outcomes (PROs).

Key Points: 
  • LAS VEGAS, March 7, 2023 /PRNewswire/ -- In the first study to establish patient satisfaction after outpatient total joint arthroplasty (TJA) in an academic medical center (AMC) setting, patients indicated they were very likely to undergo the outpatient procedure again and had high patient reported outcomes (PROs).
  • The study, "Patient Satisfaction and Outcomes following Outpatient Joint Arthroplasty in Academic Medical Centers," presented at the 2023 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, also showed that patients had short discharge times and low readmission rates after outpatient total joint arthroplasty.
  • "Academic medical centers historically haven't done TJAs on a same day basis," said lead author Soham Ghoshal, medical student, Harvard Medical School, Boston.
  • AMCs have the advantage that should a patient need to be admitted for further observation, that transition can easily be done."

Live Remote Cardiac MRI Exam to Showcase Vista.ai's Automated and Virtual Scan Capabilities at ACC.23/WCC

Retrieved on: 
Vendredi, mars 3, 2023
COVID, Hospital, European Heart Journal: Cardiovascular Imaging, Heart, MRI, Cardiac magnetic resonance imaging, Automation, CST, Cone Health Women's Hospital, Congress, Brigham, American College, Stanford University Medical Center, ACC, Harvard University, Penn State University College of Medicine, American College of Cardiology, Inflammation, Splenic infarction, COVID-19, AI, CMR, Myocarditis, Patient, Medical imaging, Cardiology

NEW ORLEANS, March 3, 2023 /PRNewswire/ -- Vista.ai, a pioneer and leader in automated MRI solutions, today announced that Dr. Michael Salerno, Chief, Cardiovascular Imaging at Stanford Health Care, will conduct a live remote cardiac MRI (CMR) scan using the company's One Click MRI™ software at the American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology (ACC.23/WCC). Dr. Salerno will scan a patient at Stanford Health in Palo Alto, Calif., virtually from the ACC.23/WCC Future Hub stage in New Orleans at 11 a.m. CST on March 5, 2023.

Key Points: 
  • One Click MRI's benefits include simple, streamlined workflows and improved image consistency, so any MRI technologist can complete a cardiac scan in a regular mixed-use MRI time slot.
  • "With Vista.ai's One Click MRI, CMRs are much more efficient and streamlined, which greatly improves our ability to scan patients who need them.
  • In addition to simplifying clinical workflows and shortening scan times, One Click MRI allows technologists, wherever they are available, to conduct a patient scan at a remote hospital, so long as the facility has an MRI scanner.
  • While One Click MRI is initially focused on automating and simplifying a CMR exam, Vista.ai recently announced planned expansion beyond the heart to other anatomies and clinical areas.

Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

Retrieved on: 
Mercredi, mars 1, 2023
Clinical trial, Tacrolimus, American Osteopathic Board of Ophthalmology and Otolaryngology, Coronavirus Scientific Advisory Board, DMD, Cone Health Women's Hospital, Associate, UCSF, MHS, Infection, Research, Immunity, Disease, IND, Oral medicine, Harvard School of Dental Medicine, DDS, FIU Herbert Wertheim College of Medicine, FDA, Tufts University School of Dental Medicine, Dentistry, Oral, Division, Hospital, Wake Forest School of Medicine, MPH, Oral Oncology, OLP, Oral and maxillofacial surgery, LIPO, Pharmaceutical industry, Vaccine, Doctor of Philosophy, Brigham

PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.  

Key Points: 
  • PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.
  • The five-member Board will initially focus on the development of LP-310, Lipella's product candidate for the treatment of symptomatic oral lichen planus (OLP).
  • Members of the advisory board include:
    Alessandro Villa, DDS, PhD, MPH will serve as the inaugural Chair of the Scientific Advisory Board.
  • Dr. Villa is the Chief of Oral Medicine, Oral Oncology and Dentistry at Miami Cancer Institute and Professor, Herbert Wertheim College of Medicine, Miami, FL.

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Retrieved on: 
Mercredi, février 15, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, BK, Cone Health Women's Hospital, Viral load, Viremia, VST, Patient, Safety, Hospital, Risk, BKV, Vaccine, Dentistry

In the randomized, double-blind, placebo-controlled study, posoleucel was shown to be generally well tolerated, with balanced safety across the two posoleucel dosing groups and placebo.

Key Points: 
  • In the randomized, double-blind, placebo-controlled study, posoleucel was shown to be generally well tolerated, with balanced safety across the two posoleucel dosing groups and placebo.
  • Patients who received posoleucel achieved a clinically meaningful greater decline in BK viral load compared with those receiving placebo.
  • “We believe today's results are an important and compelling milestone not just for AlloVir but for the entire kidney transplant community."
  • This Phase 2 study evaluated the safety and efficacy of posoleucel to treat BK viremia in adult kidney transplant recipients with BK viral load between 350-10,000,000 copies/mL (stratified by low (

AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook

Retrieved on: 
Mercredi, février 15, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Viral load, BK virus, Viral, Human polyomavirus 2, HBV, Wilfrid Sellars, BKV, Biomarker, Infrastructure as code, University of Pittsburgh School of Medicine, AIDS, JC, Cytomegalovirus, Infection, Trial of the century, Virus, University, HIV, Risk, Viral pneumonia, Research, Society, BK, Cone Health Women's Hospital, Pathology, George Washington University School of Medicine & Health Sciences, VST, Acceleration, Clinical Cancer Research, Patient, Hospital, Webcast, Harvard Medical School, Associate, Manuscript, EST, COVID-19, Washington University School of Medicine, Science, ASH, Gene, American Society of Nephrology, Respiratory syncytial virus, Poster, Adenovirus infection, IND, Vaccine, Pharmaceutical industry, Dentistry, Nursing, Cryptocurrency, Brigham, Medicine, Haematologica

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported full-year 2022 financial results for the period ended December 31, 2022.

Key Points: 
  • AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported full-year 2022 financial results for the period ended December 31, 2022.
  • These results are important proof of concept for the use of posoleucel in the solid organ transplant setting.
  • For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.
  • A live audio webcast of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com/events-and-presentations .

Lifepoint Health and Midi Health Collaborate to Enhance Access to Specialty Care for Women

Retrieved on: 
Mardi, février 14, 2023
Managed Care, General Health, Telemedicine, Virtual Medicine, Consumer, Hospitals, Fitness & Nutrition, Health Insurance, Nursing, Women, Seniors, FDA, Practice Management, Health, Cone Health Women's Hospital, Life, Woman, Physician, Menopause, RN, SVP, Evergreen, Telehealth, Practitioner, Patient, Hospital, PAP, Harvard Medical School, City, Cancer, Lives at Risk, Part, Riccardo Felici, UCSF, MD, Pharmaceutical industry, Silicon, LifePoint Health

Together, Lifepoint and Midi seek to fill a significant gap in care for women experiencing symptoms of perimenopause and menopause by leveraging telemedicine to serve patients across the United States.

Key Points: 
  • Together, Lifepoint and Midi seek to fill a significant gap in care for women experiencing symptoms of perimenopause and menopause by leveraging telemedicine to serve patients across the United States.
  • Once it is fully operationalized across Lifepoint’s facilities, the collaboration will deliver high-quality virtual care to thousands of women across the country.
  • “Midi connects women ages 40-65 who may live farther away from larger cities with convenient and specialized virtual care for the specific health concerns they may face as they age.
  • Midi relieves acute symptoms of menopause and works seamlessly with each patient’s care team to safeguard her long-term health.

Melax Tech and Boston Academic Center Hospital Awarded $2.5 Million Joint Grant from the National Institute of Health (NIH)

Retrieved on: 
Jeudi, février 16, 2023
Cone Health Women's Hospital, Deep learning, Physician, Alzheimer's disease, Diagnosis, Bangladesh Technical Education Board, NIH, Social, Algorithm, Patient, Hospital, Health, National Institute on Aging, Brigham and Women's Hospital, CDS, NLP, EHR, Principal investigator, Electronic health record, Health information management, Dementia, Nursing, Medical device, Brigham

HOUSTON, Feb. 16, 2023 /PRNewswire/ -- Melax Tech, a world leader in biomedical natural language processing (NLP) technology, and Brigham and Women's Hospital, an academic medical center in Boston, has been awarded a two-year $2.5 million grant by the NIH.

Key Points: 
  • HOUSTON, Feb. 16, 2023 /PRNewswire/ -- Melax Tech, a world leader in biomedical natural language processing (NLP) technology, and Brigham and Women's Hospital, an academic medical center in Boston, has been awarded a two-year $2.5 million grant by the NIH.
  • The project aims to build and validate a clinical decision support system (CDS) for early cognitive decline detection.
  • This project is supported by the National Institute On Aging of the National Institutes of Health under Award Number R44AG081006.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

New Preeclampsia Research Funded to Investigate Genetic Targets to Develop Potential Therapeutics

Retrieved on: 
Mercredi, février 8, 2023
Society, Boston Medical Center, Boston University, Cone Health Women's Hospital, Boston University Chobanian & Avedisian School of Medicine, Defence Scientific Advisory Council, Protein, Health, Pre-eclampsia, PRIME, HELLP, Division, Hospital, Infant, Cell, Fetus, Friends, Research, Family, Risk, Maternal–fetal medicine, Associate, APOL1, Apolipoprotein L1, Pregnancy, Partnership, SAN, EMPOWER, HELLP syndrome, L1, Hypertension, Visions (Grant Green album), Gynaecology, Infertility, Pharmaceutical industry, Tourism, Medicine, MD, Obstetrics

Based on the recommendations of its Scientific Advisory Council, the Preeclampsia Foundation awarded a grant totaling $99,994 USD to Wendy Kuohung, MD of Boston University.

Key Points: 
  • Based on the recommendations of its Scientific Advisory Council, the Preeclampsia Foundation awarded a grant totaling $99,994 USD to Wendy Kuohung, MD of Boston University.
  • The study is designed to potentially accelerate discovery of therapies for preeclampsia by designing placental cell lines that express variants of the APOL1 gene for drug screening.
  • "We lost our son Peter due to preeclampsia following a 29-week delivery in 2015," explained Lauren Pappas.
  • The Peter Joseph Pappas Research Grants program adds to the Preeclampsia Foundation's portfolio of research programs including the Vision Grant program for young investigators, PRIME for health services research, and EMPOWER, which helps build research capacity in low- and middle-income countries.

Varian Receives Investigational Device Exemption for Cardiac Radioablation Clinical Trial, RADIATE-VT

Retrieved on: 
Jeudi, janvier 19, 2023
Associate, Muscle tissue, Radiation, Catheter ablation, PALO, CRA, Literature, Standard of care, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Siemens Healthineers, Cardiac electrophysiology, Safety, IDE, Hospital, FDA, Randomized controlled trial, Senior, Cone Health Women's Hospital, Therapy, Patient, Food, Investigational device exemption, Clinical trial, Sale, Brigham and Women's Hospital, Arrhythmia, Harvard Medical School, Workflow, Pharmaceutical industry, Medical device, Medicine, Varian

PALO ALTO, Calif., Jan. 19, 2023 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) for the pivotal RADIATE-VTTM clinical trial. The RADIATE-VT trial will be the first international, multi-center, randomized controlled trial to evaluate the safety and efficacy of cardiac radioablation (CRA) compared to repeat catheter ablation for patients with high-risk refractory ventricular tachycardia (VT).

Key Points: 
  • PALO ALTO, Calif., Jan. 19, 2023 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) for the pivotal RADIATE-VTTM clinical trial.
  • Subjects will be randomly assigned to undergo cardiac radioablation with Varian's CRA system or catheter ablation.
  • The system is designed to support the entire cardiac radioablation workflow, including targeting, planning, and treatment delivery.
  • Because of this, some institutions have offered patients cardiac radioablation, and these single institution experiences have been reported in the literature.

Ariadne Labs Announces 2022-2023 Spark Grant Recipients

Retrieved on: 
Mercredi, janvier 11, 2023
MPH, Community, Tufts University School of Medicine, Trust, Anesthesiology, Conservation Innovation Grants, Community health worker, Cone Health Women's Hospital, University, Stroke, Language, Motivation, Reproductive biology, Death, Assistant professor, Health, EVT, Mortality, Research, Harvard Medical School, Ariadne, Doctor of Philosophy, Colorado Department of Health Care Policy and Financing, Checklist, Disease, Morbidity and mortality conference, Pivot, Social medicine, MMCS, African Health Economics and Policy Association, MPP, Triage, Communication, Safety, Hospital, Beth Israel Deaconess Medical Center, Assistant, Patient, New England Hospital for Women and Children, HMS, Science, Faculty, Pharmaceutical industry, Medicine, Management, Gynaecology, MD, Obstetrics, Policy

BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ariadne Labs today announced five recipients of the Ariadne Labs Spark Grant innovation awards for the 2022-2023 year. The Spark Grant program provides support for new and early-stage ideas focused on making health care safer, more integrated, and more equitable for all patients. Now in its tenth year, the program has funded more than 20 projects. 

Key Points: 
  • Five grants will support early-stage ideas to make health care safer, more integrated, and more equitable
    BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ariadne Labs today announced five recipients of the Ariadne Labs Spark Grant innovation awards for the 2022-2023 year.
  • The Spark Grant program provides support for new and early-stage ideas focused on making health care safer, more integrated, and more equitable for all patients.
  • The 2022-2023 recipients of the Ariadne Labs Spark Grant innovation awards are:
    Rose Molina, MD, MPH, Assistant Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School; Obstetrician-Gynecologist at Beth Israel Deaconess Medical Center and The Dimock Center; Core Faculty at Ariadne Labs
    Evidence suggests that individuals with limited English language proficiency experience lower quality maternal health care due to structural barriers and communication challenges.
  • In 2021 a Spark Grant funded initial work to develop a checklist to triage potential candidates for EVT.